Well, if you're both a molecular and clinical investigator, then you should be able to (1) do a Medline to find existing publications relating to Adcon-L, and (2) understand that there is a time factor between assessment of clinical trial results and their publication.
Am J Orthop 1998 Feb;27(2):111-20
Clinical assessment of a novel antiadhesion barrier gel: prospective,
randomized, multicenter, clinical trial of ADCON-L to inhibit
postoperative peridural fibrosis and related symptoms after lumbar
discectomy.
de Tribolet N, Porchet F, Lutz TW, Gratzl O, Brotchi J, van Alphen HA, van Acker RE, Benini A, Strommer KN,
Bernays RL, Goffin J, Beuls EA, Ross JS
Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
A prospective, multicenter, randomized, double-blind, controlled study of ADCON-L Anti-Adhesion Barrier Gel (a medical
device by Gliatech Inc, Cleveland, OH) was conducted in 298 patients undergoing first-time lumbar discectomy to evaluate the
safety and effectiveness of ADCON-L in preventing postoperative peridural fibrosis and in improving patient clinical outcome.
After lumbar discectomy, patients were randomized to receive either ADCON-L gel or nothing (control group) at the
conclusion of the surgical procedure. Six months after surgery, peridural scar was evaluated by magnetic resonance imaging,
and postoperative pain and straight-leg-raise angle were assessed. No statistically significant differences between the
ADCON-L and control groups were observed in terms of adverse events or wound healing characteristics. ADCON-L gel
was shown to be safe and to significantly inhibit peridural scar compared with the control group (P = 0.002). That peridural
scarring was reduced with ADCON-L gel was further supported by direct visualization of scar tissue at reoperation in both
groups. ADCON-L-treated patients had better clinical outcomes than did control patients. The incidence of activity-related
pain was significantly reduced (P = 0.013), straight-leg-raise examination scores were significantly improved (P = 0.024 on the
operative side and P = 0.015 on the nonoperative side), and ADCON-L reduced low back pain when it was most severe (P =
0.047) and at the end of the day (P = 0.044).
This was one of 10 references turned up from keyword "Adcon".
And this is one of 25 references that turn up if you search keyword "Gliatech"........
Eur J Pharmacol 1998 Jun 26;351(3):307-11
High antagonist potency of GT-2227 and GT-2331, new histamine H3
receptor antagonists, in two functional models.
Tedford CE, Hoffmann M, Seyedi N, Maruyama R, Levi R, Yates SL, Ali SM, Phillips JG
Gliatech, Cleveland, OH 44122, USA.
GT-2227 (4-(6-cyclohexylhex-cis-3-enyl)imidazole) and GT-2331
((1R,2R)-4-(2-(5,5-dimethylhex-1-ynyl)cyclopropyl)imidazole) were developed as new potent histamine H3 receptor
antagonists. The functional activity of these ligands on the histamine H3 receptor-mediated inhibition of neurogenic contraction
of the guinea-pig jejunum and histamine H3 receptor-mediated inhibition of norepinephrine release from guinea-pig heart
synaptosomes were investigated. GT-2227 and GT-2331 both antagonized the inhibitory effects of (R)-alpha-methylhistamine
on the contraction induced by electrical field stimulation in the guinea-pig jejunum with pA2 values of 7.9+/-0.1 and
8.5+/-0.03, respectively. In addition, GT-2227 and GT-2331 antagonized the inhibition of norepinephrine release in cardiac
synaptosomes by GT-2203 ((1R,2R)-trans-2-(1H-imidazol-4-yl)cyclopropylamine), a histamine H3 receptor agonist. The
current results demonstrate the antagonist activity for both GT-2227 and GT-2331 in two functional assays for histamine H3
receptors. |
